Saturday 17 October 2026
Export CGEM’s income statement to Excel — free account
Cullinan Therapeutics, Inc.
CGEM Healthcare Biotechnology
In the quarter to June 2026, EPS grew 24.3% and free cash flow grew 33.7%, each against the same quarter a year earlier.
12.93
1.07
−7.64%
Follow CGEM
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
— | — | — | — |
EV/Sales |
— | — | — | — | |
EV/FCF |
— | — | — | — | |
Quick Ratio |
10.15 | 10.01 | 10.01 | 8.23 | |
Current Ratio |
10.45 | 10.25 | 10.28 | 8.42 | |
Net Debt/EBITDA |
5.99 | 6.85 | 6.56 | 5.85 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.73 | 0.75 | 0.93 | 0.71 | |
Capex/Depreciation |
(0.48) | (0.14) | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow Yield |
— | — | — | — | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.62) | (0.65) | (0.76) | (0.62) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.62) | (0.65) | (0.76) | (0.62) | |
Cash per Share |
5.63 | 6.40 | 5.82 | 5.44 | |
Shareholders Equity per Share |
7.64 | 6.92 | 6.06 | 5.23 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
7.64 | 6.92 | 6.06 | 5.23 | |
Free Cash Flow |
(36.91) | (38.12) | (46.04) | (38.22) | |
Working Capital |
309.48 | 349.02 | 326.25 | 301.35 | |
Capital Expenditures |
(0.04) | (0.01) | — | — | |
Net Current Asset Value |
309.48 | 347.11 | 324.60 | 299.94 | |
EV/EBIT |
— | — | — | — | |
Capex to Sales |
0.00 | 0.00 | — | — | |
| Other line items | |||||
Average Payables |
1.92 | 1.26 | 2.96 | 3.09 | |
Average Assets |
568.69 | 535.10 | 491.33 | 442.06 | |
Average Common Equity |
539.62 | 499.53 | 459.01 | 406.95 |
Columns are period end dates